Psoriasis News and Research

Latest Psoriasis News and Research

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

Researchers report encouraging results from T1DAL study on type 1 diabetes

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby MD, PhD from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology.

23 Sep 2013

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years.

18 Sep 2013

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis.

18 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Scientists reveal structure of protein essential for triggering necroptosis

Scientists in Melbourne, Australia, have revealed the structure of a protein that is essential for triggering a form of programmed cell death called necroptosis, making possible the development of new drugs to treat chronic inflammatory diseases such as Crohn's disease and rheumatoid arthritis.

6 Sep 2013

Karo Wins First Milestone For Autoimmune Disease Deal With Pfizer

...

5 Sep 2013

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

...

3 Sep 2013

AARDA study reveals mothers antibodies may cause autism in babies

A new, large-scale study of more than 2,700 mothers of children with autism shows that about one in 10 mothers have antibodies in their bloodstream that react with proteins in the brain of their babies.

29 Aug 2013

Lipidor announces positive results from Phase I/IIa study of AKVANO/calcipotriol for psoriasis vulgaris

Today Lipidor announced positive results from a Phase I/IIa study investigating the efficacy and tolerability of its AKVANO/calcipotriol spray formulation for the treatment of psoriasis vulgaris, the most common form of psoriasis.

27 Aug 2013

Dermatology researcher receives NIH grant to investigate role of nervous system in psoriasis

Dermatology researcher Nicole Ward, PhD, has earned her third National Institutes of Health grant in a year - including two that scored in the first percentile. With this most recent award, an R21, she will investigate the role the nervous system plays in psoriasis - an inflammatory autoimmune disease characterized by raised areas of red, scaly, itchy and sometimes painful patches of skin.

17 Aug 2013

New proteins help patients to get more accurate diagnosis of MS

A group of proteins identified by researchers at Stockholm's KTH Royal Institute of Technology could play a role in helping multiple sclerosis patients get more accurate diagnostics about the severity and progress of their disease.

14 Aug 2013

LMU immunologists develop new technique to fight against tumors, autoimmune diseases

Immunologists at Ludwig-Maximilians-Universitaet (LMU) in Munich have come up with a new technique that can be used both to fight tumors and to treat autoimmune diseases. A new grant from the Federal Ministry for Education and Research will enable the method to be developed further.

14 Aug 2013

Dermatologists provide tips to help psoriasis patients

For people with psoriasis, a chronic skin condition, taking good care of their skin can alleviate some of the discomfort that may be experienced, such as itching, cracking and bleeding of the skin. While managing the skin condition can be a challenge, dermatologists provide tips to help psoriasis patients experience relief.

14 Aug 2013

Summer sun rays is one of the best treatments for psoriasis

Sun exposure is usually discouraged due to harmful rays causing skin cancer and premature aging but for the 7.5 million Americans suffering from psoriasis, the sun is a natural medication.

7 Aug 2013

MedPharm receives new patents for MedSpray topical spray-on-film technology

MedPharm Ltd, the topical drug development specialist, today announced it has been granted a series of further patents for its novel MedSpray topical spray-on-film technology for dermatological, topical and transdermal drug delivery.

6 Aug 2013

New treatment options give hope to people with psoriasis

Psoriasis expert and researcher Steve Feldman, M.D., says there are many new treatment options giving hope to the millions of people who suffer from the chronic skin condition.

31 Jul 2013

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Anacor Pharmaceuticals announced today that on July 26, 2013 it submitted its New Drug Application to the U.S. Food and Drug Administration for tavaborole, its drug candidate for the topical treatment of onychomycosis. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

30 Jul 2013

HONEI review shows that high glycemic index foods can exacerbate acne

A review carried out by the University of Hull has shed new light on the relationship between acne and diet. Published in Dermatological Nursing, the comprehensive review assesses the latest evidence and findings about the effects of food and nutrition on acne and suggest that high glycemic index foods such as milk could exacerbate the skin condition.

25 Jul 2013